174 related articles for article (PubMed ID: 31962202)
1. Design, synthesis and biological evaluation of erythrina derivatives bearing a 1,2,3-triazole moiety as PARP-1 inhibitors.
Li S; Li XY; Zhang TJ; Zhu J; Xue WH; Qian XH; Meng FH
Bioorg Chem; 2020 Mar; 96():103575. PubMed ID: 31962202
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of homoerythrina alkaloid derivatives bearing a triazole moiety as PARP-1 inhibitors and as potential antitumor drugs.
Li S; Li XY; Zhang TJ; Kamara MO; Liang JW; Zhu J; Meng FH
Bioorg Chem; 2020 Jan; 94():103385. PubMed ID: 31669094
[TBL] [Abstract][Full Text] [Related]
3. Novel 4,5-dihydrospiro[benzo[c]azepine-1,1'-cyclohexan]-3(2H)-one derivatives as PARP-1 inhibitors: Design, synthesis and biological evaluation.
Li S; Li XY; Zhang TJ; Zhu J; Liu KL; Wang DP; Meng FH
Bioorg Chem; 2021 Jun; 111():104840. PubMed ID: 33780687
[TBL] [Abstract][Full Text] [Related]
4. Development of erythrina-based PARP-1/FTase dual-target inhibitors against lung cancer epithelial-mesenchymal transition (EMT) in vivo and in vitro.
Yu L; Wang YD; Yan ZW; Zhang LY; Li S
Bioorg Chem; 2024 Jul; 148():107480. PubMed ID: 38772291
[TBL] [Abstract][Full Text] [Related]
5. Development of novel synthesized phthalazinone-based PARP-1 inhibitors with apoptosis inducing mechanism in lung cancer.
Almahli H; Hadchity E; Jaballah MY; Daher R; Ghabbour HA; Kabil MM; Al-Shakliah NS; Eldehna WM
Bioorg Chem; 2018 Apr; 77():443-456. PubMed ID: 29453076
[TBL] [Abstract][Full Text] [Related]
6. Discovery of quinazoline-2,4(1H,3H)-dione derivatives as novel PARP-1/2 inhibitors: design, synthesis and their antitumor activity.
Zhou J; Ji M; Yao H; Cao R; Zhao H; Wang X; Chen X; Xu B
Org Biomol Chem; 2018 May; 16(17):3189-3202. PubMed ID: 29648554
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, biological evaluation of novel piperidine-based derivatives as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors.
Lin C; Liu C; Hu P; Zou Z; Sun G
Bioorg Chem; 2024 Jul; 148():107455. PubMed ID: 38772289
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of novel phthalazinone derivatives as potent poly(ADP-ribose)polymerase 1 inhibitors.
Xin M; Sun J; Huang W; Tang F; Liu Z; Jin Q; Wang J
Future Med Chem; 2020 Oct; 12(19):1691-1707. PubMed ID: 33012191
[No Abstract] [Full Text] [Related]
9. Novel tricyclic poly (ADP-ribose) polymerase-1/2 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis and biological evaluation.
Li H; Hu Y; Wang X; He G; Xu Y; Zhu Q
Bioorg Med Chem; 2016 Oct; 24(19):4731-4740. PubMed ID: 27561983
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design of new poly (ADP-ribose) polymerase (PARP-1) inhibitors.
Chadha N; Jaggi AS; Silakari O
Mol Divers; 2017 Aug; 21(3):655-660. PubMed ID: 28653128
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of novel molecules as potent PARP-1 inhibitors.
Shen H; Ge Y; Wang J; Li H; Xu Y; Zhu Q
Bioorg Med Chem Lett; 2021 Sep; 47():128169. PubMed ID: 34091044
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design, synthesis, and evaluation of inhibitors with high selectivity for PARP-1 over PARP-2.
Yu J; Luo L; Hu T; Cui Y; Sun X; Gou W; Hou W; Li Y; Sun T
Eur J Med Chem; 2022 Jan; 227():113898. PubMed ID: 34656898
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of 4-amidobenzimidazole acridine derivatives as dual PARP and Topo inhibitors for cancer therapy.
Yuan Z; Chen S; Chen C; Chen J; Chen C; Dai Q; Gao C; Jiang Y
Eur J Med Chem; 2017 Sep; 138():1135-1146. PubMed ID: 28763648
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and evaluation of potential inhibitors for poly(ADP-ribose) polymerase members 1 and 14.
Kam CM; Tauber AL; Levonis SM; Schweiker SS
Future Med Chem; 2020 Dec; 12(24):2179-2190. PubMed ID: 33225736
[TBL] [Abstract][Full Text] [Related]
15. Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1).
Zhang Z; Chang X; Zhang C; Zeng S; Liang M; Ma Z; Wang Z; Huang W; Shen Z
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1606-1615. PubMed ID: 32779949
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of novel PARP-1 inhibitors based on pyridopyridazinone scaffold.
Elmasry GF; Aly EE; Awadallah FM; El-Moghazy SM
Bioorg Chem; 2019 Jun; 87():655-666. PubMed ID: 30952061
[TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis and Activity Evaluation of New Phthalazinone PARP Inhibitors.
Huang M; Ren J; Wang Y; Chen X; Yang J; Tang T; Yang Z; Li X; Ji M; Cai J
Chem Pharm Bull (Tokyo); 2021; 69(7):620-629. PubMed ID: 34193711
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, biological evaluation and molecular docking study of novel urea-based benzamide derivatives as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors.
Lu G; Nie W; Xin M; Meng Y; Gu J; Miao H; Cheng X; Chan ASC; Zou Y
Eur J Med Chem; 2022 Dec; 243():114790. PubMed ID: 36183505
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and evaluation of phthalazinone thiohydantoin-based derivative as potent PARP-1 inhibitors.
Zhong Y; Meng Y; Xu X; Zhao L; Li Z; You Q; Bian J
Bioorg Chem; 2019 Oct; 91():103181. PubMed ID: 31404795
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of benzodiazepines as brain penetrating PARP-1 inhibitors.
Yu J; Gou W; Shang H; Cui Y; Sun X; Luo L; Hou W; Sun T; Li Y
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):952-972. PubMed ID: 35317687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]